Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00275509 · ClinicalTrials.gov registry record · Phase 3
Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
A Phase 3 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 3
- Development phase
- 56
- Enrollment target
NCT00275509: Completed Phase 3 study, sponsored by Johns Hopkins University.
NCT00275509 is a Phase 3 study that has completed, run by Johns Hopkins University. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00275509, a Phase 3 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the anti-T cell antibody, Thymoglobulin is a more effective induction medication than the anti-IL-2R inhibitor daclizumab, in kidney transplant recipients who have a positive crossmatch with their live donor.
Interventions
- DRUG Thymoglobulin
- DRUG Tacrolimus
- DRUG Mycophenolate mofetil
- DRUG Daclizumab
- OTHER Plasmapheresis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2007-01 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00275509
The ClinicalTrials.gov registry entry for NCT00275509 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Thymoglobulin is the first listed.
NCT00275509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00275509 about?
NCT00275509 is a clinical study titled "Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch". The purpose of this study is to determine whether the anti-T cell antibody, Thymoglobulin is a more effective induction medication than the anti-IL-2R inhibitor daclizumab, in kidney transplant recipients who have a positive crossmatch with their live donor.
What is the current status of trial NCT00275509?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 56 participants. The study started on 2007-01. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00275509?
The interventions under investigation include: Thymoglobulin (DRUG), Tacrolimus (DRUG), Mycophenolate mofetil (DRUG), Daclizumab (DRUG), Plasmapheresis (OTHER).
Who is sponsoring clinical trial NCT00275509?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.